Europe’s Stoxx 600 inches lower amid French political crisis
Procept Biorobotics Corp (PRCT) stock has reached a new 52-week low, trading at 36.88 USD. This marks a significant downturn for the company, which has experienced a 56.27% decrease in its stock price over the past year. According to InvestingPro data, despite the price decline, the company maintains robust revenue growth of 55.71% and a strong balance sheet with a current ratio of 9.21. The decline reflects broader challenges faced by the company in the market, as investors continue to weigh potential risks and opportunities within the medical technology sector. While analyst price targets suggest significant upside potential, with targets ranging from $51 to $85, InvestingPro analysis indicates the stock is currently trading near its Fair Value. The 52-week low underscores the volatility and pressures that Procept Biorobotics has encountered, as it navigates a competitive landscape and seeks to regain investor confidence. Get access to 6 additional InvestingPro Tips and a comprehensive Pro Research Report for deeper insights into PRCT’s financial health and market position.
In other recent news, Procept BioRobotics reported its second-quarter 2025 earnings, surpassing expectations with an earnings per share (EPS) of -$0.35 compared to the forecasted -$0.41. The company’s revenue also exceeded projections, coming in at $79.2 million against an anticipated $76.12 million. Despite these positive results, the company is facing some challenges. Wells Fargo has adjusted its price target for Procept BioRobotics to $58.00 from $75.00, citing a delay in expected system replacements. Management no longer anticipates any system replacements in the latter half of 2025, revising earlier expectations of approximately 10 replacements this year. Meanwhile, Oppenheimer has upgraded Procept BioRobotics from Perform to Outperform, setting a price target of $60.00. The research firm noted that the recent stock selloff was overdone, presenting an attractive risk-reward scenario for long-term investors. These developments reflect a mixed outlook for the company amid its recent financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.